The Science Behind Orexin (Hypocretin) Agonists, and the Search for Potential New Treatments

Dr. Deborah Hartman details the science behind orexin (hypocretin) agonists and why it's leading researchers to develop new treatments. Dr. Deborah Hartman is the global scientific head of the Orexin Program at Centessa Pharmaceuticals. She's a PhD and a neuroscientist by training with over 20 years in leading drug development research in the biotech and pharmaceutical industry. Dr. Hartman was previously chief scientific officer at Orexia Therapeutic which is now part of Centessa. Earlier, she was vice-president and global program leader at Takeda Pharmaceuticals, leading the Orexin Program from 2017 to 2020. Dr. Hartman held prior research roles at AstraZeneca as VP of respiratory and inflammation research in the UK, VP of projects in innovative medicines for infectious diseases in Cambridge, Massachusetts, and VP of lead generation enabling sciences, also in the UK. Dr. Deborah Hartman started her career in drug discovery at Hoffmann-La Roche in Basel, Switzerland in neuroscience research and worked briefly in metabolic diseases research in Nutley, New Jersey. Dr. Hartman received her bachelor's degree from Princeton University. She holds a PhD in molecular and cellular biology from Yale University. If this video is helpful to you, please consider donating to HF. Your donation makes these resources possible! https://www.hypersomniafoundation.org...